药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lumiracoxib
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Vemurafenib.
Lumiracoxib
Pilsicainide
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Vemurafenib.
Lumiracoxib
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Vemurafenib.
Lumiracoxib
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Vemurafenib.
Lumiracoxib
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Vemurafenib.
Lumiracoxib
Delafloxacin
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Vemurafenib.
Lumiracoxib
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Vemurafenib.
Lumiracoxib
CUDC-907
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Vemurafenib.
Lumiracoxib
Anisodamine
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Vemurafenib.
Lumiracoxib
Pazufloxacin
The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Vemurafenib.
Lumiracoxib
Rupatadine
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Vemurafenib.
Lumiracoxib
Bilastine
The risk or severity of QTc prolongation can be increased when Bilastine is combined with Vemurafenib.
Lumiracoxib
Difloxacin
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Vemurafenib.
Lumiracoxib
Sarafloxacin
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Vemurafenib.
Lumiracoxib
Phosmet
The risk or severity of QTc prolongation can be increased when Phosmet is combined with Vemurafenib.
Lumiracoxib
Orbifloxacin
The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Vemurafenib.
Lumiracoxib
Fenthion
The risk or severity of QTc prolongation can be increased when Fenthion is combined with Vemurafenib.
Lumiracoxib
Famphur
The risk or severity of QTc prolongation can be increased when Famphur is combined with Vemurafenib.
Lumiracoxib
Dichlorvos
The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Vemurafenib.
Lumiracoxib
Coumaphos
The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Vemurafenib.